ARDS News and Press, Aridis Pharmaceuticals Inc. From 03/26/21

Aridis Pharmaceuticals Interview to Air on Bloomberg Television U.S. on the RedChip Money Report® PR Newswire LOS GATOS, Calif. , March 26, 2021 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the disc...

Microcap Aridis Pharmaceuticals, Inc. (ARDS) has entered into an outlicensing and product discovery agreement with privately held Kermode Biotechnologies, Inc. for vaccines and monoclonal antibodies (mAbs) that could be used for the treatment of zoonotic viruses.Zoonotic viruses are those fou...

Aridis Enters into APEX™ Licensing and Product Discovery Agreement for Zoonotic Viruses with Kermode PR Newswire LOS GATOS, Calif. , March 8, 2021 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS) today announced that it has entered into an out-l...

Cerecor Inc. (CERC) has climbed ~11.3% in the pre-market after announcing final efficacy data from a Phase 2 trial for the monoclonal antibody, CERC-002 in patients hospitalized with COVID-19 associated pneumonia and mild to moderate acute respiratory distress syndrome (AR...

Aridis Pharmaceuticals Provides Multiple Program Updates Including the Addition of a Second Inhaled Antibody to Neutralize Newly Emerging COVID-19 Mutated Variants National Institute of Allergy and Infectious Disease (NIAID) and the Coronavirus Immunotherapy Consortium (CoVIC) a...

Therapeutic Solutions International (TSOI) shares up nearly 13% premarket after announcing the acquisition of the JadiCell, cell therapy, for use in the treatment of acute respiratory distress syndrome and other lung pathologies.Chief Medical Officer James Veltmeyer talked...

Edesa Biotech ([[EDSA]] +14.4%) has secured a commitment of up to C$14M from the Government of Canada to complete the Phase 2 portion of a Phase 2/Phase 3 clinical study of its investigational drug, EB05, for the treatment of hospitalized COVID-19 patients.The funding will also help fund cert...

Aridis Pharmaceuticals to Host Fireside Chat with Analysts to Discuss 2021 Outlook for its Lead Programs and Novel mAb Discovery Platform on December 4th, 2020 PR Newswire SAN JOSE, Calif., Nov. 24, 2020 SAN JOSE, Calif. , Nov. 24, 2020 /PRNewswire/ -- A...

Aridis Pharmaceuticals (ARDS): Q3 GAAP EPS of -$0.65 misses by $0.02.Cash and equivalents was $6.2MPress Release For further details see: Aridis Pharmaceuticals EPS misses by $0.02

Aridis Pharmaceuticals Announces Third Quarter 2020 Results PR Newswire SAN JOSE, Calif., Nov. 20, 2020 SAN JOSE, Calif. , Nov. 20, 2020 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and deve...